Women and Diabetes: Preventing Heart Disease in a New Era of Therapies
Despite major advances in cardiovascular research over the past decade, women with type 2 diabetes have a high risk of cardiovascular events. Several factors contribute to the poor prognosis for women, including higher levels of frailty and comorbidities, but their cardiovascular risk is underestima...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2021-10-01
|
| Series: | European Cardiology Review |
| Online Access: | https://www.ecrjournal.com/articleindex/ecr.2021.22 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850104260829642752 |
|---|---|
| author | Giuseppe Galati Pierre Sabouret Olga Germanova Deepak L Bhatt |
| author_facet | Giuseppe Galati Pierre Sabouret Olga Germanova Deepak L Bhatt |
| author_sort | Giuseppe Galati |
| collection | DOAJ |
| description | Despite major advances in cardiovascular research over the past decade, women with type 2 diabetes have a high risk of cardiovascular events. Several factors contribute to the poor prognosis for women, including higher levels of frailty and comorbidities, but their cardiovascular risk is underestimated and there is suboptimal implementation and uptitration of new evidence-based therapies, leading to high morbidity and mortality. Recent studies highlight the need for better management of diabetes in women that can be pursued and achieved in light of recent results from randomised controlled trials demonstrating evidence of the benefits of new therapeutic strategies in improving cardiovascular outcomes and quality of life of women covering the entire cardiovascular continuum. This review critically discusses the multiple benefits for women of new pharmacological treatments, such as glucagon-like peptide-1 receptor agonists, sodium–glucose cotransporter type 2 inhibitors (SGLT2i), proprotein convertase subtilisin/kexin type 9 inhibitors, inclisiran, icosapent ethyl and bempedoic acid in preventing cardiovascular events, and treatments, such as angiotensin receptor neprilysin inhibitors, SGLT2i, vericiguat and omecamtiv mecarbil, for preventing heart failure. |
| format | Article |
| id | doaj-art-ec4ff1ff8efb43c3b5eb45f3380f1784 |
| institution | DOAJ |
| issn | 1758-3756 1758-3764 |
| language | English |
| publishDate | 2021-10-01 |
| publisher | Radcliffe Medical Media |
| record_format | Article |
| series | European Cardiology Review |
| spelling | doaj-art-ec4ff1ff8efb43c3b5eb45f3380f17842025-08-20T02:39:22ZengRadcliffe Medical MediaEuropean Cardiology Review1758-37561758-37642021-10-011610.15420/ecr.2021.22Women and Diabetes: Preventing Heart Disease in a New Era of TherapiesGiuseppe Galati0Pierre Sabouret1Olga Germanova2Deepak L Bhatt3Heart Failure Unit and Division of Cardiology, Cardiothoracic and Vascular Department, San Raffaele Hospital and Scientific Institute (IRCCS), Milan, ItalyHeart Institute, Cardiology Department, Pitié-Salpétrière, Sorbonne University and Collège National des Cardiologues Français, Paris, FranceDepartment of Diagnostic Medicine and Imaging, Samara State Medical University, Samara, RussiaBrigham and Women’s Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA, USDespite major advances in cardiovascular research over the past decade, women with type 2 diabetes have a high risk of cardiovascular events. Several factors contribute to the poor prognosis for women, including higher levels of frailty and comorbidities, but their cardiovascular risk is underestimated and there is suboptimal implementation and uptitration of new evidence-based therapies, leading to high morbidity and mortality. Recent studies highlight the need for better management of diabetes in women that can be pursued and achieved in light of recent results from randomised controlled trials demonstrating evidence of the benefits of new therapeutic strategies in improving cardiovascular outcomes and quality of life of women covering the entire cardiovascular continuum. This review critically discusses the multiple benefits for women of new pharmacological treatments, such as glucagon-like peptide-1 receptor agonists, sodium–glucose cotransporter type 2 inhibitors (SGLT2i), proprotein convertase subtilisin/kexin type 9 inhibitors, inclisiran, icosapent ethyl and bempedoic acid in preventing cardiovascular events, and treatments, such as angiotensin receptor neprilysin inhibitors, SGLT2i, vericiguat and omecamtiv mecarbil, for preventing heart failure.https://www.ecrjournal.com/articleindex/ecr.2021.22 |
| spellingShingle | Giuseppe Galati Pierre Sabouret Olga Germanova Deepak L Bhatt Women and Diabetes: Preventing Heart Disease in a New Era of Therapies European Cardiology Review |
| title | Women and Diabetes: Preventing Heart Disease in a New Era of Therapies |
| title_full | Women and Diabetes: Preventing Heart Disease in a New Era of Therapies |
| title_fullStr | Women and Diabetes: Preventing Heart Disease in a New Era of Therapies |
| title_full_unstemmed | Women and Diabetes: Preventing Heart Disease in a New Era of Therapies |
| title_short | Women and Diabetes: Preventing Heart Disease in a New Era of Therapies |
| title_sort | women and diabetes preventing heart disease in a new era of therapies |
| url | https://www.ecrjournal.com/articleindex/ecr.2021.22 |
| work_keys_str_mv | AT giuseppegalati womenanddiabetespreventingheartdiseaseinaneweraoftherapies AT pierresabouret womenanddiabetespreventingheartdiseaseinaneweraoftherapies AT olgagermanova womenanddiabetespreventingheartdiseaseinaneweraoftherapies AT deepaklbhatt womenanddiabetespreventingheartdiseaseinaneweraoftherapies |